PuraMed BioScience®, Inc., is a pharmaceutical company specializing in the research, development, and marketing of safe, highly effective, non-prescription medicinal and healthcare products with the purpose of reaching and improving the quality of life for underserved populations in the OTC marketplace.
By applying hard science to natural products, PuraMed BioScience is committed to the establishment of a leadership position in the OTC natural and alternative health remedy market by introducing a safe and effective product line” that delivers better performance with fewer side effects than its chemical counterparts.
PuraMed BioScience recently formed a new division within the company to research, develop, and distribute a line of products incorporating hemp-derived cannabinoids as key components. The company plans to launch additional cannabinoid-enhanced, anti-inflammatory and anxiolytic products as it moves forward in the development of its CBD product line.
PuraMed BioScience, Inc., employs the use of double-blind placebo controlled testing to establish efficacy and safety benchmarks for products made with natural ingredients. Using this information, PuraMed BioScience directs marketing efforts directly to the consumer, retail, and product-related patient populations.
LipiGesic M, PuraMed’s flagship formulation, is a homeopathic medication using feverfew and ginger delivered sublingually (under the tongue) for the relief of migraine pain and associated symptoms. This initial product from the company has been clinically tested and featured in three (3) top-tier medical journals with articles authored by America’s leading migraine headache experts.
Based on the results of the clinical trials, LipiGesic M has an efficacy that is comparable to the top-selling triptan medication. However, LipiGesic M has an excellent safety profile, is non-drowsy and has no reported interactions with other medications. With this initial product, PuraMed BioScience has met the criteria the company set to create a superior natural product that works better than its chemical counterpart in the resolution of migraine pain and associated symptoms.
About the Company
PuraMed BioScience was established to capture two unique opportunities. The first is to build a substantial and profitable business with the distribution of LipiGesic® M a formulation created for the acute relief of migraine headaches. PuraMed BioScience is also reviewing several third-party health and wellness products that can be incorporated into the company’s product offering. Each of these is effective and addresses a very large OTC consumer market, collectively well over $2 billion in the U.S. Each product will be unique in its class.
The second, longer-term, opportunity is to establish a leadership position in the highly fragmented OTC natural and alternative-health remedy market by introducing a “new kind of product line.” The PuraMed BioScience product line will consist of ‘alternative’ remedies for common ailments. With effective messaging campaigns, these products have the potential to be adopted by the majority, many of whom prefer ‘natural’ alternatives, provided there is no need to sacrifice performance or convenience.
Each member of the PuraMed BioScience management team brings decades of experience needed to compete in the over-the-counter and alternative health industry. This experience includes product development, drug formulation, direct marketing, sales, regulatory compliance and approval, and senior management of both public and private companies.
PuraMed BioScience® Inc., intends to execute according to the following seven-step strategy.
1. Identify effective products with large market opportunities.
2. Employ a unique and effective delivery system.
3. Perform clinical trials and obtain clinical results to overcome consumer skepticism.
4. Employ a direct-response sales campaign to refine the consumer message and generate initial revenue.
5. Achieve broad, retail distribution to provide easy and widespread consumer access.
6. Apply effective marketing to drive consumer awareness and the buying impulse.
7. Capture “first-mover” advantage.